50 results on '"Bezares, S"'
Search Results
2. Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
3. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)
4. Mutational profile from circulating tumor DNA in triple negative breast cancer: Results from the prospective registry of unresectable locally advanced or metastatic breast cancer GEICAM/2014-03 (RegistEM)
5. Geicam/2014-03 (registem): A prospective registry of advanced breast cancer: A subset of triple negative breast cancer patients with her2 low expression
6. Geicam/2014-03 (RegisTEM): A prospective registry of unresectable locally advanced or metastatic breast cancer: Characteristics of a subset of patients with triple negative subtype
7. Characteristics of HR+/HER2-patients with recurrent disease from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
8. 94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study
9. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
10. Analysis of bi-weekly oxaliplatin + folinic acid (FA) + 5-fluorouracil (FU) in metastatic gastrointestinal (GI) carcinoma.
11. Significant clinical acivity of salvage therapy with vinorelbine (VNR) + folinic acid (FA) + 5-fluoruracil (FU) in heavily and minimally pretreated patients with metastatic breast carcinoma.
12. Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer
13. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer
14. Psychological distress and health-related quality of life in women recently diagnosed with breast cancer in the Epi-GEICAM study
15. Abstract P3-09-08: Overeating and breast cancer risk by pathologic subtypes: EpiGEICAM study
16. Tumor microenvironment biomarkers as therapeutic strategies for TNBC
17. Abstract OT3-02-07: A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive advanced breast cancer (BC) sensitive to endocrine therapy (ET). “The FLIPPER study” (GEICAM/2014-12)
18. 268P - Psychological distress and health-related quality of life in women recently diagnosed with breast cancer in the Epi-GEICAM study
19. 1704PD - Tumor microenvironment biomarkers as therapeutic strategies for TNBC
20. Estudio del efecto del 25 hidroxicalciferol sobre la calcificación del cascaron y la producción de huevo
21. Efecto del reemplazo de pasta de soya por pasta de semilla de calabaza en dietas para aves.
22. El valor alimenticio del alga espirulina (spirulina geitleri) en dietas para pollos de engorda
23. Valor pigmentante y nutritivo del alga espirulina en dietas para gallinas en postura
24. Valor de la gallinaza calcinada como fuente de calcio y fosforo en dietas para aves.
25. Valor de la gallinaza en dietas para pollas en crecimiento y gallinas en postura
26. Efecto de niveles de furazolidona en producción de carne y huevo
27. Melaza con inhibidores de la fermentación alcohólica en dietas practicas para aves
28. El valor nutritivo del frijol texturizado (Phaseolus vulgaris)
29. Efecto de la adición de gallinaza a dietas para pollos en crecimiento
30. 248/249 INVITED Clinical phase I-II and pharmacokinetic study of plitidepsin in children with malignant tumors
31. Preliminary data of a phase I-II clinical and pharmacokinetic study of plitidepsin in children with malignant tumors. On behalf of the European ITCC (Innovative Therapies for Children with Cancer) Consortium
32. Combined treatment with biphosphonates, low-dose chemotherapy, and trastuzumab in receptor-negative breast cancer patients with bone marrow involvement
33. Phase II study of Gemcitabine, Ifosfamide plus Vinorelbine (GIN) as a first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): A promising non-cisplatin based regimen
34. Carcinomatosis meníngea con celularidad y bioquímica normales en líquido cefalorraquídeo
35. Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study.
36. Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
37. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.
38. Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGEICAM Study.
39. Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study.
40. Case Studies in Physiology: Training adaptation in an elite athlete after breast cancer diagnosis.
41. Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study.
42. Trajectories of alcohol consumption during life and the risk of developing breast cancer.
43. Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study.
44. Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study.
45. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
46. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.
47. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.
48. Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer.
49. Review of a promising new agent--pemetrexed disodium.
50. [Meningeal carcinomatosis with a normal cell count and biochemistry in the cerebrospinal fluid].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.